Zoe Hunter
Northwestern University
12 Papers
80 Citations
Zoe Hunter is an academic researcher from Northwestern University. The author has contributed to research in topics: T cell & Experimental autoimmune encephalomyelitis. The author has an hindex of 11, co-authored 12 publications. Previous affiliations of Zoe Hunter include University of New Mexico.
Chat about Author
Papers
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis
Daniel R. Getts,Aaron Martin,Derrick P. McCarthy,Rachael L. Terry,Zoe Hunter,Woon Teck Yap,Meghann Teague Getts,Michael A. Pleiss,Xunrong Luo,Nicholas J. C. King,Lonnie D. Shea,Stephen D. Miller +11 more
TL;DR: It is shown that antigen-decorated microparticles (500-nm diameter) induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis, highlighting the potential for using microp articles to target natural apoptotic clearance pathways to inactivate pathogenic T cells and halt the disease process in autoimmunity.
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.
Zoe Hunter,Derrick P. McCarthy,Woon Teck Yap,Christopher T. Harp,Daniel R. Getts,Lonnie D. Shea,Stephen D. Miller +6 more
TL;DR: The ability of biodegradable poly(lactic-co-glycolic acid) (PLG) nanoparticles to function as a safe, cost-effective, and highly efficient alternative to cellular carriers for the induction of antigen-specific T cell tolerance is shown.
282
Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.
Charles B. Smarr,Woon Teck Yap,Tobias Neef,Ryan M. Pearson,Zoe Hunter,Igal Ifergan,Daniel R. Getts,Paul J. Bryce,Lonnie D. Shea,Stephen D. Miller +9 more
TL;DR: In this paper, antigen-associated nanoparticles (Ag-NPs) were used to prevent and treat Th1/Th17-mediated autoimmune disease, and they were also effective for the induction of tolerance in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.
89
Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice.
Su Ji Jeong,John G. Cooper,Igal Ifergan,Tammy L. McGuire,Dan Xu,Zoe Hunter,Sripadh Sharma,Derrick P. McCarthy,Stephen D. Miller,John A. Kessler +9 more
TL;DR: The findings implicate early-infiltrating hematogenous monocytes as highly selective contributors to fibrosis that do not play an indispensable role in gliosis after SCI and suggest that the nanoparticles potentially offer a practical treatment for human spinal cord injury.
56
Targeted immunomodulation using antigen-conjugated nanoparticles.
TL;DR: In order to elicit the desired, beneficial immune response, considerations should be made at every step of the design process: the NP platform itself, ligands, and other modifiers, the delivery route, and the immune cells that will encounter the conjugated NPs can all impact host immune responses.